{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:26:16Z","timestamp":1791660376710,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated efficacy and good tolerability in patients with episodic migraine in previous phase 3 trials. We report results from the PERSIST study, which was designed to assess the efficacy and safety of galcanezumab in patients with episodic migraine from China, India, and Russia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This phase 3 study was conducted at 40 centers in China (<jats:italic>n\u2009=<\/jats:italic>\u200926), India (<jats:italic>n\u2009=<\/jats:italic>\u200910), and Russia (<jats:italic>n\u2009=<\/jats:italic>\u20094). Eligible adult patients with episodic migraine were randomized in a\u00a01:1 ratio to receive monthly galcanezumab 120\u00a0mg (with 240\u00a0mg loading dose) or placebo during a double-blind, 3-month treatment period. The primary endpoint was the overall mean change from baseline in monthly migraine headache days (MHDs). Key secondary endpoints were the mean proportion of patients with\u2009\u2265\u200950%,\u2009\u2265\u200975%, and 100% reductions from baseline in MHDs and mean change in the Migraine-Specific Quality of Life Questionnaire (MSQ) Role Function-Restrictive domain score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 520 patients were randomized and received at least one dose of galcanezumab (<jats:italic>N\u2009=<\/jats:italic>\u2009261) or placebo (<jats:italic>N\u2009=<\/jats:italic>\u2009259). The least squares (LS) mean reduction from baseline in monthly MHDs over 3\u00a0months was significantly greater with galcanezumab compared with placebo (-3.81\u00a0days vs. -1.99\u00a0days;<jats:italic>p\u2009&lt;<\/jats:italic>\u20090.0001). Significantly greater mean proportions of patients with galcanezumab versus placebo had\u2009\u2265\u200950%,\u2009\u2265\u200975%, and 100% reductions from baseline in MHDs (all<jats:italic>p\u2009&lt;<\/jats:italic>\u20090.0001). The overall mean improvement from baseline in MSQ Role Function-Restrictive score over 3\u00a0months was significantly greater with galcanezumab versus placebo (<jats:italic>p\u2009&lt;<\/jats:italic>\u20090.0001). There were no clinically meaningful differences between the\u00a0galcanezumab and placebo group on any safety parameters except for a higher incidence of injection site pruritus (5.0% vs. 0.0%), injection site reaction (3.8% vs. 0.4%), and injection site discomfort (2.3% vs. 0.0%). TEAEs related to injection sites were mild in severity, except in 1 patient who had a moderate injection site reaction. Six serious adverse events were reported by 6 patients (2 galcanezumab, 4 placebo).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Galcanezumab 120\u00a0mg once monthly was effective and well tolerated in patients with episodic migraine from China, India, and Russia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03963232?term=03963232&amp;draw=2&amp;rank=1\">NCT03963232<\/jats:ext-link>(PERSIST), registered May 24, 2019.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10194-022-01458-0","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T01:38:24Z","timestamp":1658972304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study"],"prefix":"10.1186","volume":"23","author":[{"given":"Bo","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingmin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"1458_CR1","unstructured":"GBD 2016 Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):954\u201376"},{"key":"1458_CR2","doi-asserted-by":"crossref","unstructured":"Yao C et al (2019) Burden of headache disorders in China, 1990\u20132017: findings from the Global Burden of Disease Study 2017. J Headache Pain 20(1):102","DOI":"10.1186\/s10194-019-1048-2"},{"issue":"5","key":"1458_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343\u2013349","journal-title":"Neurology"},{"issue":"1","key":"1458_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z et al (2018) Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain 19(1):10","journal-title":"J Headache Pain"},{"issue":"1\u20132","key":"1458_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jns.2011.11.021","volume":"315","author":"X Li","year":"2012","unstructured":"Li X et al (2012) Diagnosis and treatment status of migraine: a clinic-based study in China. J Neurol Sci 315(1\u20132):89\u201392","journal-title":"J Neurol Sci"},{"issue":"1","key":"1458_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-020-01117-2","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu S et al (2020) Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain 21(1):53","journal-title":"J Headache Pain"},{"key":"1458_CR7","doi-asserted-by":"crossref","unstructured":"Eigenbrodt AK et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol (8):501-51","DOI":"10.1038\/s41582-021-00509-5"},{"issue":"1","key":"1458_CR8","first-page":"17","volume":"99","author":"H Ha","year":"2019","unstructured":"Ha H, Gonzalez A (2019) Migraine headache prophylaxis. Am Fam Physician 99(1):17\u201324","journal-title":"Am Fam Physician"},{"issue":"1","key":"1458_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20(1):22\u201333","journal-title":"J Manag Care Pharm"},{"issue":"8","key":"1458_CR10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1526-4610.2011.01985.x","volume":"51","author":"P Rizzoli","year":"2011","unstructured":"Rizzoli P, Loder EW (2011) Tolerance to the beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanisms. Headache 51(8):1323\u20131335","journal-title":"Headache"},{"issue":"3","key":"1458_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pharmthera.2009.09.003","volume":"124","author":"CM Villal\u00f3n","year":"2009","unstructured":"Villal\u00f3n CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 124(3):309\u2013323","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1458_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48\u201356","journal-title":"Ann Neurol"},{"issue":"2","key":"1458_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28(2):183\u2013187","journal-title":"Ann Neurol"},{"issue":"1","key":"1458_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH et al (2002) CGRP may play a causative role in migraine. Cephalalgia 22(1):54\u201361","journal-title":"Cephalalgia"},{"issue":"8","key":"1458_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH et al (2021) Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs 35(8):805\u2013820","journal-title":"CNS Drugs"},{"issue":"7","key":"1458_CR16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102421989601","volume":"41","author":"K Drellia","year":"2021","unstructured":"Drellia K et al (2021) Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia 41(7):851\u2013864","journal-title":"Cephalalgia"},{"issue":"9","key":"1458_CR17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL et al (2018) Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"8","key":"1458_CR18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V et al (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454","journal-title":"Cephalalgia"},{"issue":"24","key":"1458_CR19","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221","journal-title":"Neurology"},{"issue":"10","key":"1458_CR20","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825","journal-title":"Lancet Neurol"},{"key":"1458_CR21","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","DOI":"10.1177\/0333102417738202"},{"key":"1458_CR22","unstructured":"Speck R et al (2021) The Migraine-Specific Quality of Life Questionnaire, Role Function Restrictive Domain: Defining Clinically Meaningful Categories of Functional Impairment Severity. J Headache Pain 22(Supp 1): P0226."},{"key":"1458_CR23","doi-asserted-by":"crossref","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology, Revised. 217-22. National Institute of Mental Health, Psychopharmacology Research Branch. Rockville.","DOI":"10.1037\/e591322011-001"},{"issue":"9","key":"1458_CR24","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1526-4610.2001.01156.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB et al (2001) Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 41(9):854\u2013861","journal-title":"Headache"},{"issue":"9","key":"1458_CR25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1046\/j.1468-2982.2000.00117.x","volume":"20","author":"P Tfelt-Hansen","year":"2000","unstructured":"Tfelt-Hansen P et al (2000) Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20(9):765\u201386","journal-title":"Cephalalgia"},{"key":"1458_CR26","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33(9):629-808","DOI":"10.1177\/0333102413485658"},{"issue":"3","key":"1458_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","volume":"27","author":"L Stovner","year":"2007","unstructured":"Stovner L et al (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27(3):193\u2013210","journal-title":"Cephalalgia"},{"issue":"8","key":"1458_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/03331024221076481","volume":"42","author":"S Kwon","year":"2022","unstructured":"Kwon S, Gil YE, Lee MJ (2022) Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia 42(8):705\u2013714","journal-title":"Cephalalgia"},{"issue":"1","key":"1458_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01458-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T20:13:28Z","timestamp":1676232808000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01458-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1458"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01458-0","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"8 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PERSIST study was conducted in accordance with the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical Guidelines, International Conference on Harmonisation guidelines for Good Clinical Practice, and applicable local laws and regulations. Patients provided written informed consent before undergoing any study procedures. The appropriate institutional review board for each participating site approved the study protocol, patient consent form and other relevant documents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JZ is a full-time employee of Eli Lily and Company. SY serves as associated editor of the Journal of Headache and Pain and as a\u00a0member of the International Headache Society. ZJ has no competing interests. BH, GL, XL, SW, TY, XL, HZ, and SY declare receiving\u00a0clinical research fees from Eli Lilly and Company for participating as investigators in the PERSIST study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}